8-K: BioLargo Reports Record 2024 Revenues, Up 45% Year-Over-Year

BioLargo announced record revenues for 2024, marking the tenth consecutive year of revenue growth, with a 45% increase over the previous year.

Summary

• BioLargo, Inc. reported record revenues for the year ended December 31, 2024.
• Revenues reached $17,779,000, a 45% increase compared to 2023.
• This marks the tenth consecutive year of revenue growth for the company.
• The net loss for 2024 was $4,347,000, a 6% decrease year-over-year, with $3,490,000 attributed to Clyra Medical's operations.
• Non-cash expenses, primarily from stock and stock option issuances, amounted to $2,479,000, representing 57% of the net loss.
• The company reduced its reliance on equity financing, issuing 42% fewer shares in 2024 compared to 2023.
• As of December 31, 2024, stockholders' equity was $6,056,000, assets totaled $10,513,000, and liabilities were $4,457,000.
• The company had $4,489,000 in working capital and $3,548,000 in cash and cash equivalents.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenues and reduced reliance on equity financing. While there are net losses, the decrease in losses and focus on future growth initiatives contribute to a favorable sentiment.

Positives

• Record revenues for the year ended December 31, 2024, reaching $17,779,000.
• 45% increase in revenue compared to 2023.
• Tenth consecutive year of revenue growth.
• Net loss decreased by 6% year-over-year.
• Reduced reliance on equity financing, with 42% fewer shares issued compared to 2023.
• Clyra Medical is making progress towards a national rollout of its surgical irrigation products.

Negatives

• The company experienced a net loss of $4,347,000 in 2024.
• $3,490,000 of the net loss was from Clyra Medical's operations.
• Non-cash expenses (issuance of stock and stock options) were $2,479,000 (57% of net loss).

Risks

• The company's performance is subject to regional economic conditions.
• BioLargo operates in highly competitive markets subject to rapid technological change.
• The company's success depends on managing frequent product introductions and transitions.
• The company relies on the performance of its distributors.

Future Outlook

BioLargo is excited about its emerging products, including Clyra surgical products, its water treatment solution for PFAS contamination, and its Cellinity battery energy storage technology.

Management Comments

• Were proud to report the tenth year in a row of record revenues in our 10-K filed yesterday, said Dennis P. Calvert, the companys President and CEO.
• With over $5 million cash generated by our odor control products, we were able to reduce our reliance on equity financing.
• But, were most excited about our emerging products, such as the Clyra surgical products, our water treatment solution for the global PFAS contamination crisis, and our safe, long-lasting battery energy storage technology we call Cellinity.

Industry Context

BioLargo operates in the cleantech and life sciences sectors, focusing on environmental solutions. The company's focus on PFAS contamination and water treatment aligns with increasing global concerns about water quality and environmental sustainability.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific sub-sectors BioLargo's various products compete in.
• For example, in the PFAS treatment space, companies like Aclara Technologies and Kurita Water Industries are key players, but their overall financial profiles and business models may differ significantly from BioLargo's.
• Similarly, in the odor control market, companies like Ecolab and Steris offer competing solutions, but they are much larger and more diversified.
• BioLargo's 45% revenue growth is impressive, but it's important to consider the company's smaller size and the specific market segments it targets when comparing it to industry giants.

Stakeholder Impact

• Shareholders will likely view the record revenues and reduced reliance on equity financing positively.
• Employees may benefit from the company's growth and expansion into new markets.
• Customers can expect continued innovation and development of sustainable technologies.
• Suppliers may see increased demand for their products and services as BioLargo expands its operations.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Continue progress towards a national rollout of Clyra Medical's surgical irrigation products.
• Further develop and commercialize emerging products like the water treatment solution for PFAS contamination and Cellinity battery energy storage technology.
• Monitor and manage risks related to economic conditions, competition, and reliance on distributors.

Key Dates

Keywords

BioLargo, revenues, cleantech, PFAS, water treatment, odor control, energy storage, Clyra Medical, surgical irrigation, financial results